Sinda/Fluint Stratfied Tank Modeling

A general purpose SINDA/FLUINT (S/F) stratified tank model was created and used to simulate the Ksite1 LH2 liquid self-pressurization tests as well as axial jet mixing within the liquid region of the tank. The S/F model employed the use of stratified layers, i.e. S/F lumps, in the vapor ullage as well as in the liquid region. The model was constructed to analyze a general purpose stratified tank that could incorporate the following features: Multiple or singular lumps in the liquid and vapor regions of the tank, Real gases (also mixtures) and compressible liquids, Venting, pressurizing, and draining, Condensation and evaporation/boiling, Wall heat transfer, Elliptical, cylindrical, and spherical tank geometries. Extensive user logic was used to allow for tailoring of the above features to specific cases. Most of the code input for a specific case could be done through the Registers Data Block

One Dimensional Analysis Model of a Condensing Spray Chamber Including Rocket Exhaust Using SINDA/FLUINT and CEA

Modeling droplet condensation via CFD codes can be very tedious, time consuming, and inaccurate. CFD codes may be tedious and time consuming in terms of using Lagrangian particle tracking approaches or particle sizing bins. Also since many codes ignore conduction through the droplet and or the degradating effect of heat and mass transfer if noncondensible species are present, the solutions may be inaccurate. The modeling of a condensing spray chamber where the significant size of the water droplets and the time and distance these droplets take to fall, can make the effect of droplet conduction a physical factor that needs to be considered in the model. Furthermore the presence of even a relatively small amount of noncondensible has been shown to reduce the amount of condensation. It is desirable then to create a modeling tool that addresses these issues. The path taken to create such a tool is illustrated. The application of this tool and subsequent results are based on the spray chamber in the Spacecraft Propulsion Research Facility (B2) located at NASA's Plum Brook Station that tested an RL-10 engine. The platform upon which the condensation physics is modeled is SINDAFLUINT. The use of SINDAFLUINT enables the ability to model various aspects of the entire testing facility, including the rocket exhaust duct flow and heat transfer to the exhaust duct wall. The ejector pumping system of the spray chamber is also easily implemented via SINDAFLUINT. The goal is to create a transient one dimensional flow and heat transfer model beginning at the rocket, continuing through the condensing spray chamber, and finally ending with the ejector pumping system. However the model of the condensing spray chamber may be run independently of the rocket and ejector systems detail, with only appropriate mass flow boundary conditions placed at the entrance and exit of the condensing spray chamber model. The model of the condensing spray chamber takes into account droplet conduction as well as the degrading effect of mass and heat transfer due to the presence of noncondensibles. The one dimension model of the condensing spray chamber makes no presupposition on the pressure profile within the chamber, allowing the implemented droplet physics of heat and mass transfer coupled to the SINDAFLUINT solver to determine a transient pressure profile of the condensing spray chamber. Model results compare well to the RL-10 engine pressure test data

Concise Review: Stem Cell Therapies for Amyotrophic Lateral Sclerosis: Recent Advances and Prospects for the Future

Amyotrophic lateral sclerosis (ALS) is a lethal disease involving the loss of motor neurons. Although the mechanisms responsible for motor neuron degeneration in ALS remain elusive, the development of stem cell‐based therapies for the treatment of ALS has gained widespread support. Here, we review the types of stem cells being considered for therapeutic applications in ALS, and emphasize recent preclinical advances that provide supportive rationale for clinical translation. We also discuss early trials from around the world translating cellular therapies to ALS patients, and offer important considerations for future clinical trial design. Although clinical translation is still in its infancy, and additional insight into the mechanisms underlying therapeutic efficacy and the establishment of long‐term safety are required, these studies represent an important first step toward the development of effective cellular therapies for the treatment of ALS. S tem C ells 2014;32:1099–1109Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/106861/1/stem1628.pd

Intraspinal stem cell transplantation for amyotrophic lateral sclerosis

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/134502/1/ana24584_am.pdfhttp://deepblue.lib.umich.edu/bitstream/2027.42/134502/2/ana24584.pd

Economic Perspectives on Personalized Health Care and Prevention

The objective of this paper is to provide an overview of economic evaluation of personalized medicine, focusing particularly on the use of cost-effectiveness analysis and other methods of valuation. We draw on insights from the literature and our work at the University of California, San Francisco Center for Translational and Policy Research on Personalized Medicine (TRANSPERS). We begin with a discussion of why personalized medicine is of interest and challenges to adoption, whether personalized medicine is different enough to require different evaluation approaches, and what is known about the economics of personalized medicine. We then discuss insights from TRANSPERS research and six areas for future research

Stem cell technology for neurodegenerative diseases

Over the past 20 years, stem cell technologies have become an increasingly attractive option to investigate and treat neurodegenerative diseases. In the current review, we discuss the process of extending basic stem cell research into translational therapies for patients suffering from neurodegenerative diseases. We begin with a discussion of the burden of these diseases on society, emphasizing the need for increased attention toward advancing stem cell therapies. We then explain the various types of stem cells utilized in neurodegenerative disease research, and outline important issues to consider in the transition of stem cell therapy from bench to bedside. Finally, we detail the current progress regarding the applications of stem cell therapies to specific neurodegenerative diseases, focusing on Parkinson disease, Huntington disease, Alzheimer disease, amyotrophic lateral sclerosis, and spinal muscular atrophy. With a greater understanding of the capacity of stem cell technologies, there is growing public hope that stem cell therapies will continue to progress into realistic and efficacious treatments for neurodegenerative diseases. Ann Neurol 2011;70: 353–361.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/86937/1/22487_ftp.pd

ER Stress in Diabetic Peripheral Neuropathy: A New Therapeutic Target

Significance: Diabetes and other diseases that comprise the metabolic syndrome have reached epidemic proportions. Diabetic peripheral neuropathy (DPN) is the most prevalent complication of diabetes, affecting ?50% of diabetic patients. Characterized by chronic pain or loss of sensation, recurrent foot ulcerations, and risk for amputation, DPN is associated with significant morbidity and mortality. Mechanisms underlying DPN pathogenesis are complex and not well understood, and no effective treatments are available. Thus, an improved understanding of DPN pathogenesis is critical for the development of successful therapeutic options. Recent Advances: Recent research implicates endoplasmic reticulum (ER) stress as a novel mechanism in the onset and progression of DPN. ER stress activates the unfolded protein response (UPR), a well-orchestrated signaling cascade responsible for relieving stress and restoring normal ER function. Critical Issues: During times of extreme or chronic stress, such as that associated with diabetes, the UPR may be insufficient to alleviate ER stress, resulting in apoptosis. Here, we discuss the potential role of ER stress in DPN, as well as evidence demonstrating how ER stress intersects with pathways involved in DPN development and progression. An improved understanding of how ER stress contributes to peripheral nerve dysfunction in diabetes will provide important insight into DPN pathogenesis. Future Directions: Future studies aimed at gaining the necessary insight into ER stress in DPN pathogenesis will ultimately facilitate the development of novel therapies. Antioxid. Redox Signal. 21, 621?633.Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/140287/1/ars.2013.5807.pd

Autocrine Production of IGF‐I Increases Stem Cell‐Mediated Neuroprotection

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder resulting in motor neuron (MN) loss. There are currently no effective therapies; however, cellular therapies using neural progenitor cells protect MNs and attenuate disease progression in G93A‐SOD1 ALS rats. Recently, we completed a phase I clinical trial examining intraspinal human spinal stem cell (HSSC) transplantation in ALS patients which demonstrated our approach was safe and feasible, supporting the phase II trial currently in progress. In parallel, efforts focused on understanding the mechanisms underlying the preclinical benefit of HSSCs in vitro and in animal models of ALS led us to investigate how insulin‐like growth factor‐I (IGF‐I) production contributes to cellular therapy neuroprotection. IGF‐I is a potent growth factor with proven efficacy in preclinical ALS studies, and we contend that autocrine IGF‐I production may enhance the salutary effects of HSSCs. By comparing the biological properties of HSSCs to HSSCs expressing sixfold higher levels of IGF‐I, we demonstrate that IGF‐I production augments the production of glial‐derived neurotrophic factor and accelerates neurite outgrowth without adversely affecting HSSC proliferation or terminal differentiation. Furthermore, we demonstrate that increased IGF‐I induces more potent MN protection from excitotoxicity via both indirect and direct mechanisms, as demonstrated using hanging inserts with primary MNs or by culturing with organotypic spinal cord slices, respectively. These findings support our theory that combining autocrine growth factor production with HSSC transplantation may offer a novel means to achieve additive neuroprotection in ALS. Stem Cells 2015;33:1480–1489Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/111155/1/stem1933.pd

Intraspinal neural stem cell transplantation in amyotrophic lateral sclerosis: Phase 1 trial outcomes

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/106747/1/ana24113.pd